semaglutide fatty liver disease India has approved Wegovy (semaglutide 2.4 mg) for treating MASH (metabolic dysfunction-associated steatohepatitis)—a serious form of that can silently progress to liver damage if left untreated. MASH develops when Semaglutide 2·4 mg once weekly

Studies have shown that individuals using Semaglutide GLP-1 can experience significant weight loss when combined with a healthy diet and regular exercise

Three branded semaglutide products currently exist: Ozempic (injection, 0.25 mg to 2 mg weekly) for type 2 diabetes and cardiovascular risk reduction Wegovy (injection, up to 2.4 mg weekly) for long-term weight management in obese or overweight adults Rybelsus (oral tablet, 3 mg to 14 mg daily) for type 2 diabetes Compounded semaglutide, which some U.S

Some people experience rapid early progress, while others lose weight more gradually over time

Lipomas are benign tumors that respond well to surgical treatment and should not be life-limiting for dogs

Nielsen R, Moller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, Harms HJ, Frokiaer J, Eiskjaer H, Jespersen NR, et al

While direct combination data with GLP-1 receptor agonists remain limited and still evolving, the mechanistic rationale is straightforward: if GLP-1 therapy is driving significant weight loss and a meaningful fraction of that loss would otherwise come from muscle, then supporting testosterone levels provides a biologically coherent way to shift the composition of that loss toward fat rather than lean tissue